The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

M Rudwaleit,1 D van der Heijde,2 R Landewé,3 N Akkoc,4 J Brandt,5 C T Chou,6 M Dougados,7 F Huang,8 J Gu,9 Y Kirazli,10 F Van den Bosch,11 I Olivieri,12 E Roussou,13 S Scarpato,14 I J Sørensen,15 R Valle-Oñate,16 U Weber,17 J Wei,18 J Sieper,1,19 M Rudwaleit, Department of Correspondence to Germany Research Center, Berlin, Germany 19 German Rheumatology Zurich, Switzerland Bogotá, Colombia 16 University Militar Hospital, Copenhagen, Denmark 14 M Scarlato Hospital, Scafati, Italy 13 King George Hospital, London, UK 11 University Hospital, Izmir, Turkey Izmir, Turkey 10 University of Ege, Izmir, Turkey 12 University Hospital Ghent, Gent, Belgium 11 University Hospital, Maastricht, The Netherlands 10 University Hospital, Leiden, The Netherlands 9 Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 8 Chinese PLA General Hospital, Beijing, China 7 Hospital Cochin, Paris, France 6 Dokuz Eylül University Hospital, Izmir, Turkey 5 M Scarlato Hospital, Scafati, Italy 4 Dokuz Eylül University Hospital, Izmir, Turkey 3 Maastricht University Medical Center, Maastricht, The Netherlands 2 Leiden University Medical Center, Leiden, The Netherlands 1 University Hospital, Ghent, Belgium

ABSTRACT

Objective To evaluate new classification criteria for peripheral spondyloarthritis (SpA) in patients with SpA with peripheral manifestations only.

Methods In this Assessment of SpondyloArthritis international Society (ASAS) study, two prespecified sets of criteria were compared against the European Spondylarthropathy Study Group (ESSG) and Amor criteria in newly referred consecutive patients with undiagnosed peripheral arthritis, and/or enthesitis, and/or dactylitis that usually began before 45 years of age. The clinical diagnosis (SpA vs no SpA) made by the ASAS rheumatologist served as reference standard.

Results In all, 24 ASAS centres included 266 patients, with a final diagnosis of SpA being made in 66.2%. After adjustments a final set of criteria showed the best balance between sensitivity (77.8%) and specificity (82.9%): arthritis and/or enthesitis and/or dactylitis plus (B) two or more other parameters: arthritis, enthesitis, dactylitis, inflammatory back pain in the past, family history of SpA. The new criteria performed better than modified versions of the ESSG (sensitivity 82.5%, specificity 81.1%) and the Amor criteria (sensitivity 39.8%, specificity 97.8%), particularly regarding sensitivity. In the entire ASAS population of 975 patients the combined use of ASAS criteria for axial SpA and ASAS criteria for peripheral SpA also had a better balance (sensitivity 79.5%, specificity 83.3%) than the modified ESSG (sensitivity 79.1%, specificity 88.8%) and Amor criteria (sensitivity 67.5%, specificity 86.7%), respectively.

Conclusions The new ASAS classification criteria for peripheral SpA performed well in patients presenting with peripheral arthritis, enthesitis and/or dactylitis.

Within ASAS there was great interest to also develop criteria for patients with SpA with predominant peripheral manifestations and to compare these with the European Spondylarthropathy Study Group (ESSG) and Amor criteria, both of which have been generated in the early 1990s as classification criteria not specifically for peripheral SpA but for the entire group of SpA that includes peripheral SpA (for details of these criteria see Sieper et al or visit the ASAS slide library at http://www.asas-group.org). This ASAS project resulted in new classification criteria for peripheral SpA, which are presented in this paper.

METHODS

Study design

ASAS rheumatologists were invited to participate. Patients with peripheral manifestations including peripheral arthritis, and/or enthesitis, and/or dactylitis, that usually began before 45 years of age and absence of back pain were included if they were new referrals to the rheumatology department and did not have an established diagnosis but only suspicion of SpA such as arthritis of the lower limb or asymmetric arthritis. Thus, the study protocol was similar to that of the axial arm of the study. To minimise selection bias it was required that patients were included in a strictly consecutive manner. After written informed consent was obtained a diagnostic investigation was performed, and the results including the final diagnosis were documented in a case report form.

Clinical, laboratory and imaging data

Peripheral arthritis, enthesitis and dactylitis were assessed clinically. Joints affected by arthritis were marked on a 64-joint manikin. The Mander index was used for enthesitis. For dactylitis the affected finger or toe was documented. In addition, the following other SpA features were assessed: past inflammatory back pain (IBP) as judged by the rheumatologist, history of uveitis, psoriasis, IBP, preceding gastrointestinal or urogenital infection and a positive family history of SpA (presence in a first-degree or second-degree relative of (1) AS, (2) reactive arthritis, (3) psoriasis, (4) IBP, (5) uveitis). Mandatory laboratory tests included human leukocyte antigen B27 (HLA-B27) and C reactive protein. MRI of the sacroiliac (SI) joints and plain radiographs of the pelvis were strongly recommended in order to obtain information about involvement.

Spondyloarthritis (SpA) describes a group of interrelated rheumatic conditions comprising ankylosing spondylitis (AS), psoriatic arthritis, arthritis/ spondylitis with inflammatory bowel disease (IBD) and reactive arthritis. Patients with SpA can be distinguished according to their clinical presentation as patients with predominantly axial SpA or with predominantly peripheral SpA. For patients with predominant axial disease the Assessment of SpondyloArthritis international Society (ASAS) has recently developed and validated new classification criteria for axial SpA covering patients with non-radiographic and radiographic axial SpA.
of the axial skeleton in patients with peripheral manifestations only. Radiographic sacroiliitis was graded locally according to the modified New York criteria. MRI findings were documented as the presence or absence of typical signs of active inflammation of the SI joints. The final clinical diagnosis (SpA or no SpA) was made locally by the ASAS rheumatologist who also indicated the level of confidence with this judgement on a numerical rating scale from 0 (not confident at all) to 10 (very confident).

### Candidate criteria for peripheral SpA

Two sets of candidate criteria for peripheral SpA were developed, based on clinical reasoning and tested in a limited number (n=35) of paper patients (supplementary table 1), as has been done in the previous study on axial SpA. Accordingly, patients have to have peripheral arthritis compatible with SpA, and/or enthesitis, and/or dactylitis as entry manifestation and, in addition, have to have two or more of uveitis, preceding infection, psoriasis, IBP, positive family history of SpA, HLA-B27, arthritis, enthesitis, dactylitis, IBP (past) in set 1 of the criteria. In set 2 of the candidate criteria one entry manifestation plus one or more of preceding infection, psoriasis, or IBF suffices for the fulfillment of the criteria, or plus two or more of the remaining parameters as in set 1 (see above). These prespecified candidate criteria, including some adjustments, were then tested in consecutive real patients.

### Data analysis

The expert doctor’s diagnosis (SpA vs no SpA) was used as the external (reference) standard. Multivariable logistic regression analysis was performed to identify parameters contributory to explaining variance in the classification (SpA vs no SpA). The prespecified candidate criteria for peripheral SpA were compared to the ESSG and Amor criteria using cross tables and sensitivity and specificity were calculated. Similar comparisons were made also in the entire ASAS population of 975 patients in whom the candidate criteria for peripheral SpA were applied to patients with peripheral manifestations only and the ASAS criteria for axial SpA applied to patients with predominantly axial manifestations with or without peripheral manifestations. The ESSG and Amor criteria were both modified by adding the parameter ‘active sacroiliitis on MRI’ as has been done previously.

### Performance of criteria for SpA

Table 5 shows sensitivity and specificity of the prespecified candidate criteria, of various modifications thereof, and of the ESSG and Amor criteria with their respective modifications. Both sets of prespecified candidate criteria had a good specificity (90% and 84.4%, respectively) while sensitivity was moderate only (62.5% and 67%, respectively). In comparison, the specificity of the ESSG (81.1%) and of the Amor (97.8%) criteria was also good, however, both were lacking sensitivity (55.1% and 35.2%, respectively). Modifying set 1 of the candidate criteria in that one SpA feature in addition to the entry manifestation arthritis/enthesitis/dactylitis suffices (set 1A and 1A_h) did not improve the overall performance (increase in sensitivity but decrease in specificity). However, when more weight was given...
to single variables such as psoriasis, IBD and preceding infection (prespecified set 2 of the candidate criteria), sensitivity increased (67% vs 62.5% of set 1). Thus, more weight was given to other rather specific SpA features including HLA-B27 (set 2B and 2B_h), uveitis (set 2C and 2C_h) and sacroiliitis on imaging (set 2D) in order to increase sensitivity. In fact, these modifications resulted in better balanced sensitivities and specificities with the best trade off found for set 2D (sensitivity 77.8%, specificity 82.2%) (figure 1).

The item ‘sacroiliitis on imaging’ (definite radiographic sacroiliitis or sacroiliitis on MRI according to the consensus definition9) was included in the modified candidate criteria because (1) radiographic sacroiliitis contributed independently to the classification as SpA in the regression analysis and (2) sacroiliitis on MRI appeared to be highly relevant for the classification of patients (table 1). The restriction of ‘enthesitis at any site’ to ‘enthesitis of the heel’ consistently resulted in a drop of sensitivity by 5% to 10% in all sets of criteria tested. The change of ‘enthesitis at any site’ to ‘enthesitis of the heel’ resulted in better balanced sensitivities and specificities with the best trade off found for set 2D (sensitivity 77.8%, specificity 82.2%) (figure 1).

The item ‘sacroiliitis on imaging’ (definite radiographic sacroiliitis or sacroiliitis on MRI according to the consensus definition9) was included in the modified candidate criteria because (1) radiographic sacroiliitis contributed independently to the classification as SpA in the regression analysis and (2) sacroiliitis on MRI appeared to be highly relevant for the classification of patients (table 1). The restriction of ‘enthesitis at any site’ to ‘enthesitis of the heel’ consistently resulted in a drop of sensitivity by 5% to 10% in all sets of criteria tested but a gain in specificity of around 1% only (table 3), therefore ‘enthesitis at any site’ was chosen.

### Performance of criteria in the entire ASAS study population

In the entire ASAS study on new criteria for axial and peripheral SpA a total of 975 patients (709 with undiagnosed chronic back pain with or without peripheral manifestations and 266 with undiagnosed arthritis/enthesitis/dactylitis) had been included. In the entire ASAS study population (n=975) the performance of criteria was assessed. The criteria set that performed best was set 2D (sensitivity 77.8%, specificity 82.2%) (figure 1).
Table 3  Sensitivity and specificity of the prespecified candidate criteria for peripheral SpA, ESSG, Amor and modified criteria in patients with peripheral arthritis, enthesitis and/or dactylitis in 266 patients (n=176 peripheral SpA, n=90 no SpA)

<table>
<thead>
<tr>
<th>Sets of criteria for peripheral SpA</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Set of criteria voted for by ASAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prespecified candidate criteria:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASAS candidate set 1: arthritis/enthesitis (any)/dactylitis plus ≥2 parameters</td>
<td>62.5</td>
<td>90.0</td>
<td></td>
</tr>
<tr>
<td>ASAS candidate set 1_h: arthritis/enthesitis (heel only)/dactylitis plus ≥2 parameters</td>
<td>54.0</td>
<td>91.1</td>
<td></td>
</tr>
<tr>
<td>ASAS candidate set 2: arthritis/enthesitis (any)/dactylitis plus (A) ≥1 of psoriasis, IBD, preceding infection or (B) ≥2 other parameters</td>
<td>67.0</td>
<td>84.4</td>
<td></td>
</tr>
<tr>
<td>ASAS candidate set 2_h: arthritis/enthesitis (heel only)/dactylitis plus (A) anyone of psoriasis, IBD, preceding infection or (B) ≥2 other parameters</td>
<td>56.8</td>
<td>85.6</td>
<td></td>
</tr>
<tr>
<td>Modifications of prespecified candidate criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Set 1A: arthritis/enthesitis (any)/dactylitis plus ≥1 parameter</td>
<td>92.6</td>
<td>55.6</td>
<td></td>
</tr>
<tr>
<td>Set 1A_h: arthritis/enthesitis (heel only)/dactylitis plus ≥1 parameter</td>
<td>84.7</td>
<td>61.1</td>
<td></td>
</tr>
<tr>
<td>Set 2B: arthritis/enthesitis (any)/dactylitis plus (A) ≥1 of psoriasis, IBD, preceding infection, HLA-B27, or (B) ≥2 other parameters</td>
<td>74.4</td>
<td>82.2</td>
<td></td>
</tr>
<tr>
<td>Set 2D: arthritis/enthesitis (any)/dactylitis plus (A) ≥1 of psoriasis, IBD, preceding infection, HLA-B27, or (B) ≥2 other parameters</td>
<td>67.6</td>
<td>83.3</td>
<td></td>
</tr>
<tr>
<td>Set 2C: arthritis/enthesitis (any)/dactylitis plus (A) ≥1 of psoriasis, IBD, preceding infection, HLA-B27, uveitis, or (B) ≥2 other parameters</td>
<td>75.0</td>
<td>82.2</td>
<td></td>
</tr>
<tr>
<td>Set 2C_h: arthritis/enthesitis (heel only)/dactylitis plus (A) ≥1 of psoriasis, IBD, preceding infection, HLA-B27, uveitis, or (B) ≥2 other parameters</td>
<td>68.2</td>
<td>83.3</td>
<td></td>
</tr>
<tr>
<td>Set 2D: arthritis/enthesitis (any)/dactylitis plus (A) ≥1 of psoriasis, IBD, preceding infection, HLA-B27, uveitis, sacroiliitis on imaging, or (B) ≥2 other parameters*</td>
<td>77.8</td>
<td>82.2</td>
<td>+</td>
</tr>
<tr>
<td>ESSG/Amor criteria:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESSG</td>
<td>55.1</td>
<td>81.1</td>
<td></td>
</tr>
<tr>
<td>Modified ESSG (with MRI)†</td>
<td>62.5</td>
<td>81.1</td>
<td></td>
</tr>
<tr>
<td>Amor</td>
<td>35.2</td>
<td>97.8</td>
<td></td>
</tr>
<tr>
<td>Modified Amor (with MRI)†</td>
<td>39.8</td>
<td>97.8</td>
<td></td>
</tr>
</tbody>
</table>

*Sacroiliitis on imaging refers to definite radiographic sacroiliitis according to the mod. New York criteria or sacroiliitis on MRI according to the consensus definition.8
†The ESSG criteria were modified in that active sacroiliitis on MRI was added to the list of parameters of which at least one is required in addition to inflammatory back pain or synovitis.
‡The Amor criteria were modified in that active sacroiliitis on MRI was assigned three scoring points, similar to definite radiographic sacroiliitis. Thus, presence of either definite radiographic sacroiliitis or active sacroiliitis on MRI yielded three points (maximum of three points for the imaging criterion).

Table 4 presents the results of a combination of two new criteria from ASAS, ESSG and Amor on ASAS voting.

![Arthritis or Enthesitis or Dactylitis](image)

**Figure 1** Final set of classification criteria for peripheral spondyloarthritis (SpA) (set 2D) selected by Assessment of SpondyloArthritis international Society (ASAS). The criteria are applicable to patients with peripheral arthritis (usually predominantly of the lower limbs and/or asymmetric arthritis), and/or enthesitis, and/or dactylitis. The various SpA features are defined in Table 5. In the 266 patients in this study, the sensitivity of the criteria was 77.8%, the specificity 82.2%.

between July 2006 and December 2008. A total of 650 patients had been diagnosed as having SpA, of whom 37.7% had axial involvement only, 33.5% had peripheral involvement only and 28.8% had axial and peripheral involvement. In the entire study population the performance of the new ASAS criteria was assessed as follows: for patients with back pain irrespective of peripheral manifestations we applied the new ASAS criteria for axial SpA6 and for patients with peripheral manifestations only we applied the candidate criteria set 2D. As can be seen from table 4, the combination of the two new criteria from ASAS resulted in a better balance of sensitivity and specificity than ESSG or Amor criteria (figure 2).

**ASAS voting**

At the annual meeting of ASAS in Rome in January 2009 the results were presented and discussed. The attending full ASAS members voted for (1) preference of new ASAS criteria over ESSG and Amor in patients with peripheral SpA (67% of votes), (2) preference of using candidate criteria set 2D (figure 1 and table 5) (66% of the votes) and (3) using the combination of new criteria for axial SpA in patients with predominant back pain (with or without peripheral manifestations) and new criteria set 2D for peripheral SpA for patients with peripheral manifestations only (67% of the votes).

**DISCUSSION**

In a series of papers published in the Annals of the Rheumatic Diseases we have embarked under the auspices of ASAS on the development and validation of new classification criteria for axial and peripheral SpA. For patients with axial SpA these efforts included a new definition of IBP,10 the development5 and validation6 of new classification criteria for axial SpA and the definition of active (inflammatory) sacroiliitis on MRI by a consensus approach.9 Finally, new ASAS classification criteria for patients with peripheral SpA were developed and tested which are presented herein.

The patients included in this study had peripheral arthritis, enthesitis and/or dactylitis of less than 1-year duration. All patients were new referrals, had undiagnosed disease and only suspicion of SpA. To avoid selection bias patients had to be
included in a strictly consecutive way. The final diagnosis by the local ASAS expert rheumatologist was used as the reference standard. Obviously, the rheumatologist’s diagnosis is influenced by knowledge and experience, and by already existing criteria for SpA such as the ESSG or Amor criteria. It is therefore of particular note that the ESSG and Amor criteria did not perform very well in terms of sensitivity in this study, indicating that peripheral SpA according to the opinion of the rheumatologist is not perfectly captured by these existing criteria.

Both sets of the prespecified ASAS candidate criteria had greater sensitivity (62.5% and 67%, respectively) than the ESSG and Amor criteria. However, in set 1 the requirement of two further SpA features in addition to the entry manifestation seemed to be too restrictive since a considerable proportion of patients diagnosed as having peripheral SpA had in fact only one additional SpA feature. In the prespecified candidate set 2, more weight was given to the single items psoriasis, IBD and preceding infection which already led to an increase in sensitivity. In further modifications more weight was given also to other rather specific SpA parameters including HLA-B27, uveitis and sacroiliitis on imaging, which resulted in the final set of criteria (set 2D) with a balanced sensitivity of 77.8% and a specificity of 82.2%. Since the cohort of patients was too small to be split into a ‘test’ and a ‘validation’ dataset, we could not validate the final adjustments as we did for the axial SpA criteria. Therefore, future testing of the new criteria in independent cohorts is worthwhile to overcome this limitation.

The poor sensitivity of 55% of the Amor criteria in our study may be partially explained by the fact that peripheral arthritis in the Amor criteria is strictly defined as oligoarthritis (ie, two to four joints) whereas in this ASAS study 46% of patients with SpA had either monoarthritis or polyarthritis. Furthermore, to fulfill the Amor criteria six points (ie, three to four items) are needed. This seems quite difficult to reach for patients with peripheral manifestations only, yet considered to have SpA. The ESSG criteria were also lacking sensitivity (55.1%), which may be contributable to the sole consideration of arthritis, but not enthesitis or dactylitis, as entry criterion in

**Table 4** Comparison of the combined criteria for axial SpA and for peripheral SpA (set 2D), ESSG criteria and Amor criteria in the entire ASAS study population (n=975)

<table>
<thead>
<tr>
<th>Sets of criteria for SpA</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESSG</td>
<td>66.7</td>
<td>72.0</td>
</tr>
<tr>
<td>Modified ESSG (with MRI)*</td>
<td>79.1</td>
<td>68.8</td>
</tr>
<tr>
<td>Amor</td>
<td>55.6</td>
<td>86.7</td>
</tr>
<tr>
<td>Modified Amor (with MRI)*</td>
<td>67.5</td>
<td>86.7</td>
</tr>
<tr>
<td>Combination of ASAS criteria for axial SpA (in patients with predominant back pain with or without peripheral manifestations) and criteria for peripheral SpA set 2D (arthritis/enthesitis/dactylitis plus (A) ≥1 of psoriasis, inflammatory bowel disease, preceding infection, HLA-B27, uveitis, sacroiliitis on imaging, or (B) ≥2 other parameters**) for patients with peripheral manifestations only</td>
<td>79.5</td>
<td>83.3</td>
</tr>
</tbody>
</table>

*The ESSG criteria were modified in that active sacroiliitis on MRI was added to the list of parameters of which at least one is required in addition to inflammatory back pain or synovitis.
†The Amor criteria were modified in that active sacroiliitis on MRI was assigned 3 scoring points, similar to definite radiographic sacroiliitis. Thus, presence of either definite radiographic sacroiliitis or active sacroiliitis on MRI yielded 3 points (maximum of 3 points for the imaging criterion).
‡Sacroiliitis on imaging refers to definite radiographic sacroiliitis according to the modified New York criteria or sacroiliitis on MRI according to the consensus definition.9 ASAS, Assessment of SpondyloArthritis international Society; ESSG, European Spondylarthropathy Study Group; HLA-B27, human leucocyte antigen B27; SpA, spondyloarthritis.

In patients with ≥3 months back pain (with/without peripheral manifestations) and age at onset <45 years:

- Sacroiliitis on imaging plus ≥1 SpA feature
- HLA-B27 plus ≥2 other SpA features

**Figure 2** Combined use of the Assessment of SpondyloArthritis international Society (ASAS) criteria for axial spondyloarthritis (SpA) and the ASAS criteria for peripheral SpA in the entire SpA population. In patients with predominantly axial involvement (back pain) with or without peripheral manifestations, the ASAS criteria for axial SpA are applied. In patients with peripheral manifestations only, the ASAS criteria for peripheral SpA are applied. In the entire ASAS population of 975 patients sensitivity and specificity of the combined use of the two sets of criteria were 79.5% and 83.3%, respectively.
Criteria

Table 5 Definition of SpA features for use of ASAS classification criteria for peripheral SpA

<table>
<thead>
<tr>
<th>SpA Feature</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entry criteria:</td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>Current peripheral arthritis compatible with SpA (usually asymmetric and/or predominant involvement of the lower limb), diagnosed clinically by a doctor</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>Current enthesitis, diagnosed clinically by a doctor</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>Current dactylitis, diagnosed clinically by a doctor</td>
</tr>
<tr>
<td>Additional SpA features:</td>
<td></td>
</tr>
<tr>
<td>IBP in the past*</td>
<td>IBP in the past according to the rheumatologist’s judgement</td>
</tr>
<tr>
<td>Arthritis</td>
<td>Past or present peripheral arthritis compatible with SpA (usually asymmetric and/or predominant involvement of the lower limb), diagnosed clinically by a doctor</td>
</tr>
<tr>
<td>Enthesitis†</td>
<td>Enthesitis: past or present spontaneous pain or tenderness at examination of an entheses</td>
</tr>
<tr>
<td>Uveitis</td>
<td>Past or present uveitis anterior, confirmed by an ophthalmologist</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>Past or present dactylitis, diagnosed by a doctor</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>Past or present psoriasis, diagnosed by a doctor</td>
</tr>
<tr>
<td>IBD</td>
<td>Past or present Crohn’s disease or ulcerative colitis diagnosed by a doctor</td>
</tr>
<tr>
<td>Preceding infection</td>
<td>Urethritis/cervicitis or diarrhoea within 1 month before the onset of arthritis/enthesitis/dactylitis.</td>
</tr>
<tr>
<td>Family history for SpA</td>
<td>Presence in first-degree (mother, father, siblings, brothers, children) or second-degree (maternal and paternal grandparents, aunts, uncles, nieces and nephews) relatives of any of the following: (1) ankylosing spondylitis, (2) psoriasis, (3) acute uveitis, (4) reactive arthritis, (5) IBD</td>
</tr>
<tr>
<td>HLA-B27</td>
<td>Positive testing according to standard laboratory techniques</td>
</tr>
<tr>
<td>Sacroilitis by imaging</td>
<td>Bilateral grade 2–4 or unilateral grade 3–4 sacroilitis on plain radiographs, according to the modified New York criteria, or active sacroilitis on MRI according to the ASAS consensus definition&lt;sup&gt;9&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*Here, only IBP in the past is considered. In patients with current IBP (and concomitant peripheral manifestations), the ASAS classification criteria for axial SpA should be applied.<sup>9</sup> In the ASAS classification criteria for axial SpA, current IBP was considered and defined according to the ASAS experts’ definition<sup>16</sup>: at least four out of five parameters present: (1) age at onset <40 years; (2) insidious onset; (3) improvement with exercise; (4) no improvement with rest; (5) pain at night (with improvement upon getting up).

†Any site of enthesitis can be affected whereas in the ASAS classification criteria for axial SpA only enthesitis of the heel is considered.

In our study, 14.8% of patients with SpA had enthesitis and/or dactylitis at entry without arthritis. The lack of HLA-B27 in the list of SpA parameters may further limit the sensitivity of the ESSG criteria. HLA-B27 was a very strong parameter differentiating between SpA and no SpA in our study (47.2% vs 5.6%), and was identified as a strong contributor in the logistic regression analysis. Of note, HLA-B27 was also the strongest differentiating parameter in the original ESSG study in patients with IBP and patients with peripheral arthritis, but was explicitly excluded from the formal set of the criteria at that time because the ESSG criteria were meant to be applicable in epidemiological studies without the need for human leucocyte antigen (HLA) typing.<sup>11</sup> Thus, it seems that for many rheumatologists HLA-B27 positivity is important for considering SpA in patients with back pain<sup>6,12</sup> and in patients with peripheral arthritis of the SpA type and/or enthesitis and/or dactylitis.

In order not to include too many patients with osteoarthritis we limited the age at onset to usually ≤45 years. Since a young age at onset may be more relevant in axial SpA<sup>6</sup> than in peripheral SpA in this study we did not exclude those patients (15%) who were older than 45 years at disease onset. Finally, the new ASAS criteria are unable to solve the problem of how to best classify patients with psoriasis and peripheral arthritis since these patients are likely to fulfill the ASAS criteria and also the CASPAR (for ‘CIASSification criteria for Psoriatic Arthritis’) criteria for psoriatic arthritis.<sup>13</sup>

The Amor and ESSG criteria and the new ASAS criteria were further challenged in the entire ASAS study population of 975 patients. The combined use of the new ASAS criteria for axial SpA in patients with predominant back pain with or without peripheral manifestations and of the new ASAS criteria for peripheral SpA (set 2D) in patients with peripheral manifestations only, yielded a better balance of sensitivity (79.5%) and specificity (83.3%) than the ESSG and Amor criteria did. A formal voting process at the annual ASAS meeting in 2009 revealed a preference for the new ASAS criteria for peripheral SpA over ESSG and Amor.

The relatively high prevalence of sacroilitis on imaging (either by radiographs or by MRI) was an interesting finding. None of the patients with radiographic sacroilitis (n=34) had current back pain (only seven patients had IBP in the past) and none of them had limitations of spinal mobility or of chest expansion, so none of them fulfilled the modified New York criteria for AS. Sacroilitis on MRI was also frequent but the number of patients with MRI investigation was small, and more research is needed regarding this topic. Since sacroilitis on imaging contributed to a diagnosis of SpA in our study this item was included in the criteria.

Enthesitis of the heel has been considered as highly specific for SpA and became part of the ESSG criteria<sup>9</sup> and of the ASAS criteria for axial SpA.<sup>6</sup> In the current study, however, enthesitis at sites excluding the heel, was found in 20.7% of patients. Restricting enthesitis in the various candidate criteria to the heel resulted in a drop of sensitivity by 5% to 10% with a concomitant gain in specificity of around 1% only. Therefore, the item ‘enthesitis (of any site)’ and not ‘enthesitis of the heel’ was chosen in the final set of criteria.

In summary, the new ASAS classification criteria for peripheral SpA seem to reflect better than the ESSG and Amor criteria the current perception of ASAS rheumatologists of what peripheral SpA of short duration looks like (‘gestalt’). With the entry manifestations ‘peripheral arthritis, usually of the SpA type’, ‘enthesitis’ and/or ‘dactylitis’ the criteria are comprehensive and the target population is well defined. Patients with few but typical clinical manifestations may be better captured by these criteria than with the ESSG or Amor criteria. Further studies should evaluate the performance of the new criteria in other settings.

Participants The following ASAS members who are not authors of this manuscript have contributed by inclusion of at least one patient or have participated in the paper patient exercise: J Braun, Herne, Germany; R Burgos-Vargas, Mexico City, Mexico; E Collantes-Estevez, Cordoba, Spain; J Darmawan, Semarang, Indonesia; J Davis, San Francisco, California, USA; B Dijkmans, Amsterdam, The Netherlands; K de Vlam, Leuven, Belgium; P Emery, Leeds, UK; O Fitzgerald, Dublin, Ireland; R Inman, Toronto, Canada; M A Khan, Cleveland, Ohio, USA; M Leirisalo-Repo, Helsinki, Finland; A Linssen, IJmuiden, The Netherlands; W Maksymowych, Edmonton, Alberta, Canada; C Nackerio, Scafati, Italy; R Sturrock, Glasgow, UK; I van der Horst-Bruinsma, Amsterdam, The Netherlands; S van der Linden, Maastricht, The Netherlands.
We would like to thank J Listing, Berlin, Germany, for additional statistical help.

This study was supported financially by ASAS.

None.

Ethical approval Ethical approval for the conduct of the study was obtained from local ethical committees in each centre and written informed consent was obtained from all patients.

Not commissioned; externally peer reviewed.

The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

M Rudwaleit, D van der Heijde, R Landewé, N Akkoc, J Brandt, C T Chou, M Dougados, F Huang, J Gu, Y Kirazli, F Van den Bosch, I Olivier, E Roussou, S Scarpato, I J Sørensen, R Valle-Oñate, U Weber, J Wei and J Sieper

Ann Rheum Dis 2011 70: 25-31 originally published online November 24, 2010
doi: 10.1136/ard.2010.133645

Updated information and services can be found at:
http://ard.bmj.com/content/70/1/25

These include:

Supplementary Material
Supplementary material can be found at:
http://ard.bmj.com/content/suppl/2010/10/19/ard.2010.133645.DC1

References
This article cites 13 articles, 7 of which you can access for free at:
http://ard.bmj.com/content/70/1/25#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Editor's choice (162)
- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Clinical diagnostic tests (1282)
- Immunology (including allergy) (5144)
- Inflammatory bowel disease (73)
- Ophthalmology (128)
- Pain (neurology) (883)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/